SOUTH SAN FRANCISCO, CA – May 14, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity to the patient, today announced that the first clinical data from the phase 1 study to evaluate its lead therapeutic candidate, AMV564,...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – (Business Wire) -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – December 2, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors South San Francisco, CA – November 7, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, will present at...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors South San Francisco, CA -- October 16, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell...
South San Francisco, CA —September 24, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing. The round was co-led by NanoDimension and Qiming Venture Partners...
South San Francisco, CA – July 1, 2019 -- Amphivena Therapeutics, Inc., highlighted initial data from the dose escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML, AMV564-101, NCT03144245) in an oral presentation June...
[fluid][html css="margin-top:23px;"] SOUTH SAN FRANCISCO – March 5, 2019 -- Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief...
Data Demonstrate AMV564’s Safety, Anti-Leukemic Activity, and Unique PK Profile SOUTH SAN FRANCISCO -- December 3, 2018 -- Amphivena Therapeutics, Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell engager for the treatment of Acute Myeloid...
SOUTH SAN FRANCISCO --December 9, 2017 --AmphivenaTherapeutics Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell redirector for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), will present today in an oral presentation at the 59thAnnual Meeting of the...
SOUTH SAN FRANCISCO – November 29, 2017 – Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), announced today that it has received Orphan Drug Designation from...
SOUTH SAN FRANCISCO -- September 11, 2017 -- Amphivena Therapeutics, Inc., a privately held biotechnology company developing a novel CD33/CD3-bispecific T cell engaging antibody for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), is pleased to announce three additions to the company’s...
Proprietary T-cell Redirecting Bispecific CD33/CD3 Antibody for the Treatment of AML Nears First-in-Human Study SAN FRANCISCO, CA, August 10, 2016 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND)...
Positive Preclinical Study Results Support Advancement of Amphivena’s Proprietary Bispecific CD33/CD3-Targeting Therapeutic Candidate into Clinical Development for Treatment of Acute Myeloid Leukemia (AML) SAN FRANCISCO, CA, May 26, 2015 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced that the company will present data...
Cancer Immunotherapy Development Milestones Trigger Payments to Amphivena SAN FRANCISCO, CA, April 7, 2015 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapeutics, today announced the achievement of the first and second milestones under the terms of its agreement with Janssen Biotech, Inc. Amphivena and Janssen...